{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:59:49Z","timestamp":1776463189535,"version":"3.51.2"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.04.008","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T13:46:56Z","timestamp":1498657616000},"page":"482-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens"],"prefix":"10.1016","volume":"50","author":[{"given":"Nathaniel J.","family":"Rhodes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan E.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Kiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Nicholas","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura K.","family":"Whited","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusten T.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0010","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dku001","article-title":"Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study","volume":"69","author":"Alves","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0025","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2015.03.005","article-title":"Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC","volume":"82","author":"Rhodes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0035","series-title":"Performance standards for antimicrobial susceptibility testing\u2014twenty-sixth informational supplement. Document M100-S26","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0040","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2017"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0050","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/AAC.01956-15","article-title":"Defining clinical exposures of cefepime for Gram-negative bloodstream infections that are associated with improved survival","volume":"60","author":"Rhodes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0055","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/phar.1807","article-title":"Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoeitic cell transplantation","volume":"36","author":"Whited","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0065","series-title":"An adaptive grid nonparametric approach to pharmacokinetic and dynamic (PK\/PD) population models","first-page":"389","author":"Leary","year":"2001"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0075","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","article-title":"The Hill equation: a review of its capabilities in pharmacological modelling","volume":"22","author":"Goutelle","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0085","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/jac\/dkv067","article-title":"Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis","volume":"70","author":"Rhodes","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0090","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.01520-08","article-title":"Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs","volume":"53","author":"Goutelle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0095","series-title":"MAXIPIME (cefepime hydrochloride) IV package insert","author":"Hospira","year":"2013"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0100","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.008_bib0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijantimicag.2005.09.016","article-title":"Trough serum concentrations of \u03b2-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic\/pharmacodynamic properties of \u03b2-lactams","volume":"27","author":"Navas","year":"2006","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T09:28:39Z","timestamp":1535707719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917302005"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}